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Antigen- or mitogen-stimulated T lymphocytes  produce factors that can induce 
a number of functional and biochemical modifications in macrophage popula- 
tions. These modifications include increases in endocytic, biosynthetic, secretory, 
and  effector cell  functions, as  well  as  changes in  membrane physiology and 
composition (1-4). This process has been called macrophage activation and the 
iymphokines that induce these effects are known as macrophage-activating  factors 
(MAF).' 
Over the past three years, work from several laboratories has indicated that 
gamma-interferon (IFN-3,), the [FN produced by T  lymphocytes, represents one 
type of MAF. Purified or partially purified preparations of IFN-5' produced by 
normal T  cells,  T  cell  hybridomas, or by recombinant DNA technology have 
been found to prime macrophages for nonspecific tumoricidal activity (5-11), 
induce or enhance intraceilular cytocidal reactions (12,  13), and increase expres- 
sion  of  Ia  or  DR  antigens  on  the  cell  surface  (14-16).  Using  monoclonal 
antibodies to murine recombinant IFN-% we have recently shown that IFN-'r 
represents the major and possibly only lymphokine produced by concanavalin A 
(Con A)-stimulated normal murine splenic cells or the  24/G1  murine T  cell 
hybridoma that can induce tumoricidal activity or Ia expression in macrophagesfl 
These observations have prompted an analysis of the interaction of IFN-7 with 
macrophage populations.  It is the purpose of this report to describe this inter- 
action on a functional and biochemical basis and to demonstrate the existence of 
a  IFN-~, receptor on macrophages. This receptor is capable of binding either 
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natural  or  recombinant  murine  IFN-7  in  a  specific  and  saturable  manner. 
Receptor engagement is required for the initiation of macrophage activation. 
Materials and  Methods 
Media, Supplements and Buffers.  All media, supplements, and buffers used in  these 
experiments were prepared from endotoxin-free stocks and were determined to be free 
of endotoxin using the Limulus amebocyte lysate assay  (Sigma Chemical Co.,  St.  Louis, 
MO).  To  destroy endotoxin  that  potentially  might  have  been  adherent  to  glass,  all 
autoclaved glassware  was  baked  for  3  h  at  180°C.  RPMI-1640  and  Eagle's  minimal 
essential medium were prepared from powdered stocks (Flow  Laboratories, Inglewood, 
CA) using USP sterile water (Travenol Laboratories, Inc., Deerfield, IL). Liquid Dulbec- 
co's modified Eagle's medium containing 4,500 mg glucose/liter (DME) was purchased 
from  M.A.  Bioproducts,  Walkersville,  MD.  Aseptically drawn  fetal  calf serum  (FCS, 
Rehatuin FS) was obtained from Reheis Chemical Co. (Phoenix, AZ) and heat inactivated 
(1  h,  56°C) before use.  Other media supplements included injectable penicillin G  and 
streptomycin sulfate (Eli Lilly and Co., Indianapolis, IN), injectable sodium bicarbonate 
and sodium heparin  (Gibco-Invenex Division, Chagrin  Falls,  OH),  1  M  Hepes buffer 
solution, versene, sodium pyruvate, and L-glutamine (M.A.  Bioproducts), 10 mM nones- 
sential  amino  acids  and  trypsin-EDTA (Ix) (Gibco  Laboratories,  Grand  Island,  NY), 
gentamicin (Scheering Corp., Kenilworth, N  J), indomethacin, trizma base, trizma hydro- 
chloride, 13-mercaptoethanol, ethanolamine, and saponin (Sigma Chemical Co.), sodium 
chloride, sodium mono- and dibasic-phosphate (Fisher Scientific Co., Fairlawn, N  J), bovine 
serum albumin,  Fraction V  (United States  Biochemical Co.,  Cleveland, OH),  soybean 
trypsin inhibitor (Calbiochem-Behring Corp., La Jolla, CA) and concanavalin A (Con A, 
Miles-Yeda,  Ltd., Rehovot, Israel). 
Animals.  C3HeB/FeJ, CBA/CaJ, C57BL/6J, DBA/2J, SJL, and C3H/HeJ mice, and 
Lewis rats were obtained from the breeding colony at the Research Institute of Scripps 
Clinic.  A/J,  C3D2F1/J, and Swiss (BKL) were obtained from The Jackson Laboratory, 
Bar  Harbor,  ME.  Swiss (NCS)  mice were obtained  from the  breeding colony at  The 
Rockefeller University, New York, NY.  Armenian hamsters were obtained from Cam- 
bridge Diagnostics, Cambridge, MA and guinea pigs from Crest Caviary, Raymond, CA. 
Lymphokine Preparations.  Lymphokine-containing supernatants were prepared by Con 
A stimulation of cultures of the murine T cell hybridoma 24/G1 or normal murine splenic 
cells as described previously (5). 
Recombinant Gamma Interferon.  E. coli-derived  murine IFN-3, was produced as previ- 
ously described (17). A preparation (lot number 1551/43) was used that had been purified 
to a specific antiviral activity of 7.2  ×  10  ~ IRU/mg.  IFN was stored at 4°C in  10 mM 
Tris-HCl, 0.5 M NaCI buffer, pH 8.0 containing 0.1% 13-mercaptoethanol. 
High Pressure Liquid Chromatography (HPLC) Gel Filtration of Recombinant IFN-7.  180 
t~l of the purified recombinant IFN-3, was injected into a 7.5 ×  600 mm Bio-Sil TSK250 
HPLC gel filtration column (Bio-Rad Laboratories, Richmond, CA) connected to a Waters 
HPLC system (Waters Associates, Milford, MA).  The column was eluted at 23°C with 
0.02 M phosphate-buffered physiological saline (PBS), pH 7.2, at a flow rate of 1 ml/min. 
Preparation oflodinated IFN-7.  The two-peak HPLC fractions that displayed a molec- 
ular mass of 32,000 daltons were pooled and used for radiolabeling. 14 #g of IFN in 100 
#1 was incubated with 1 mCi ~25I Bolton-Hunter reagent (18) in a "V"-shaped glass reaction 
vial (ICN Chemicals, Radioisotope Division, Irvine, CA) for 2 h at 4°C. Protein-associated 
and free 125I were separated by centrifugation through tubes containing BioGel P-6 as 
described by Fishelson et al.  (19).  Plastic tubes (10 × 75 mm, Falcon Labware, Oxnard, 
CA) pierced at the bottom with a needle were plugged with scrubbed nylon fibers (Fenwal 
Laboratories, Deerfield, IL) and packed with  BioGel P-6,  100  to 200  mesh (Bio-Rad 
Laboratories) equilibrated in PBS. The tube was then placed inside a 12 x  75-mm plastic 
tube, centrifuged to dryness for 3 min at 1,000 rpm in an Adams Sero-Fuge (Clay Adams, 
Inc., New York, NY) and the inside tube transferred to a new  12 ×  75-mm tube. The CELADA  ET  AL.  57 
labeled IFN was applied to the top of the BioGel P-6 and the tubes were centrifuged as 
above. Protein-bound, but not free, '25I was eluted from the gel by this procedure and 
collected at the bottom of the  12  X 75 mm tubes. The P-6 tube was washed once with 
100  tA of buffer and  the  two  eluted  volumes were  combined.  Recovery of IFN  was 
essentially 100% as assessed with the quantitative MAF assay. Typical preparations were 
labeled to a  specific activity of 7.6  ~Ci/ug.  ~25I-IFN-~ was stored at 4°C  and retained 
biological activity for at least 2 wk. 
Alpha and Beta Interferons.  These murine IFN were purchased from Lee Biomolecular 
Laboratories (San Diego, CA). IFN-a had a specific activity of 5 x  105 IRU/mg, and IFN- 
3of 1.5 ×  l07 IRU/mg. 
Peritoneal Macrophages.  Peritoneal  exudate cells (PEC) were harvested as described 
previously by lavage from mice that had been injected intraperitoneally 3 d  previously 
with 1.5 ml of 10% protease peptone (Difco Laboratories, Detroit, MI) (5). Rats, hamsters, 
and  guinea  pigs  were  injected  with  5%  casein  5  d  before  the  PEC  were  harvested. 
Macrophage monolayers were prepared by seeding the PEC suspension into flat-bottom 
96-well tissue culture plates (Costar, No. 3696, Cambridge, MA) or 6-well  tissue culture 
plates (Costar, No. 3506). The cells were adhered for 2 h at 37°C and the plates washed 
vigorously to remove nonadherent cells. 
Mouse Bone Marrow-derived  Macrophages.  Macrophages derived from bone marrow 
cultures  were  obtained  according  to  the  method  of Meerpohl  et  al.  (20)  with  some 
modifications. Mice were killed by cervical dislocation and both femurs were dissected 
free of adherent tissue. The ends of the bones were cut off and the marrow tissue eluted 
by  irrigation  with  PBS.  Cells  were  suspended  by  vigorous  pipetting  and  washed  by 
centrifugation,  l0 T cells were cultured  in a  nontissue culture plastic 150-mm petri dish 
(Lab-Tek 4030,  Miles Laboratories, Inc., Naperville, IL) in 50 ml of DME containing 2 
mM L-glutamine,  1 mM Na pyruvate, 50  U/ml penicillin,  50 #g/ml streptomycin, 20% 
heat-inactivated horse serum, and 30% L cell-conditioned medium. The cell suspensions 
were incubated at 37°C in a humidified 5% CO~ atmosphere. After 6-9 d, macrophages 
that were loosely adherent to the dishes were harvested with cold PBS and used. 
Human Cells.  Human peripheral blood monocytes, lymphocytes, and polymorphonu- 
clear leukocytes (PMN) were purified from heparinized, normal venous blood by discon- 
tinuous density gradient  centrifugation on FicolI-Urografin (21).  The upper layer con- 
tained a mixture of monocytes and lymphocytes, while 98% of PMN were present in the 
lower  layer.  Erythrocytes  were  obtained  at  the  bottom  of the  tube.  Monocytes were 
separated from lymphocytes by adherence onto autologous serum-treated plastic plates 
according to the  method of Fischer et al.  (22).  The purity of all cell preparations was 
>98% as assessed by cytocentrifugation and Giemsa-peroxidase staining (23). 
Preparation  of Membranes from Bone Marrow-derived  Macrophages.  Membranes were 
prepared according to the procedure of Gabel et al. (24).  In brief, cells were disrupted 
with a sonicator and the cell lysates centrifuged at 850 g for 10 min. The resulting low 
speed supernatant was then recentrifuged at 40,000 g for 30 rain. Membrane pellets were 
resuspended by homogenization and washed three times.  Membrane preparations were 
stored at -70°C. 
Cultured  Cell Lines.  The human histiocytic lymphoma cell line (U0sT) and the murine 
mastocytoma cell  line  (P815)  were  maintained  in  RPMI  supplemented  with  2  mM  e- 
glutamine, 50 U/ml penicillin, 50 #g/ml streptomycin, 1 mM Na pyruvate, 0.075% (wt/ 
vol) Na bicarbonate, and  10%  heat-inactivated FCS.  Murine T  cell  hybridomas TH4.4, 
24/G1, and  1.19 and the murine fibrosarcomas L929, TU5, and  1023  were maintained 
in DME supplemented with 2 mM L-glutamine 50 U/ml penicillin, 50 ug/ml streptomycin, 
1 mM  Na pyruvate, and  10%  FCS.  Two murine macrophage cell lines were also used: 
P388D~  was maintained in RPMI and J774 in MEM supplemented with 2 mM L-glutamine, 
1 mM pyruvate,  10  mM nonessential amino acids,  0.075%  (wt/vol) Na bicarbonate, 50 
ug/ml ofgentamicin, and 10% FCS. 
Measurement of MAF Activity.  MAF was quantitated  by measurement of its ability to 
induce  nonspecific tumorilytic activity in  peptone-elicited C3HeB/FeJ macrophages to- 
ward P815 mastocytoma cells, as detailed elsewhere (5) with some modifications, Briefly, 58  RECEPTOR  FOR  INTERFERON-'y  ON  MACROPHAGES 
reactions  were  performed  in  duplicate  or  triplicate  in  96-well  flat-bottom A/2  tissue 
culture plates in a total volume of 100 #1 (Costar, No. 3696). Each well contained 1 x  105 
adherent  macrophages, serial dilutions of MAF,  an excess of a  second signal (1  x  106 
heat-killed Listeria monocytogenes (HKLM)), 10 -6 M indomethacin and 1 x  104111  In-labeled 
P815.  llqn-oxine  chelate  was purchased from Mediphysics,  Inc.  (Bloomfield, NJ) and 
labeling was performed as described by Wiltrout et al. (25). Following incubation for 18 
h  at 37°C in a  humidified 5% CO2 atmosphere, 50 #1 of each culture supernatant was 
removed and analyzed for ~*In content.  1 U  of MAF is defined as that amount which 
produces 50% maximal specific ill in release in this assay. 
Absorption Studies.  Six-well  tissue  culture  plates  (Costar,  No.  3506)  were  used  for 
absorption of MAF.  In all the cases, plates were preincubated overnight with medium 
containing 20%  FCS before use. Six million adherent cells were incubated with  1 ml of 
MAF containing supernatant at 37°C in a humidified 5% COu atmosphere. Supernatants 
were collected and filtered through a 0.2-tim filter (Millipore Corporation, Bedford, MA) 
to remove cellular debris and  the remaining activity quantitated  using  the  tumorilytic 
assay. As the control  for these experiments,  1 ml of MAF-containing supernatant  was 
incubated without macrophages in the culture plates for the same period of time. 
Measurement of Interleukin  2 (IL-2) Activity.  IL-2 activity was  quantitated  using  the 
method of Smith (26).  Serial dilutions of the sample were cultured with 4,000 HT-2 cells, 
the IL-2-dependent murine T  cell line for 20 h  in a total volume of 200 #l.  The cells 
were then pulsed for 4  h  with [3H]thymidine (New England Nuclear, Boston, MA) and 
thymidine incorporation determined. The IL-2 standard used in these studies was a gift 
from Dr. Jacques Chiller, Lilly Research Laboratories, La Jolla, CA and contained 250 
U/ml. The amount of IL-2 present in an unknown sample was determined  by titration 
against the IL-2 standard. 
Preparation and Binding of lFN-7-coated Covaspheres to Macrophages.  100 #1 of a 1.35% 
suspension of coumarin (green) fluorescent microspheres (Covaspheres, Covalent Tech- 
nology Corp., Redwood City, CA) in PBS were mixed with 25 ~1 of purified recombinant 
IFN-'y (2.6 mg/ml) and incubated overnight at 4°C. The microspheres were pelleted by 
centrifugation for I0 min at 8,000 g in a Beckman microfuge 12 (Beckman Instruments, 
Inc., Palo Alto, CA) and washed one time with PBS containing  1% BSA. Microspheres 
were then incubated with 1 ml of 1 M ethanolamine in PBS, pH 7.0 to block any remaining 
unreacted sites on the beads. After three washes, microspheres were sonicated for 1 min 
and resuspended in  1 ml of RPMI medium and stored at 4°C  until  use.  Microspheres 
treated with ethanolamine but not IFN--y were used as controls. For binding studies, 2 x 
105 EPM were adhered for 2 h at 37 °C to coverslips (Coverslip No. 1-THK, Bellco Glass, 
Inc., Vineland, N  J) in 24-well (16-ram diameter) tissue culture plates (Costar, No. 3424). 
Coverslips were washed and 20 ul of microspheres was added in  1 ml of medium. After 
incubation  for 2  h  at 4°C,  coverslips were washed and examined under  a  microscope 
(Zeiss,  Photomicroscope Type II, Munich,  West Germany) with  ultraviolet and visible 
fight. 
Binding Studies with ~25I-recombinant IFN-7.  Five million bone marrow-derived mac- 
rophages125 or the. macrophage cell line P388D1 were incubated with different concentrauons 
of  I-IFN-7 m a total volume of 150 #1 with RPMI-supplemented medium. After 2 h at 
4 ° C, 120 tsl was applied to 250 tA of an oil mixture consisting of six parts dioctylpthalate 
and four parts dibutylpthalate (Aldrich Chemical Company, Inc., Milwaukee, WI) in 400 
#1 polyethylene microfuge tubes (VWR Scientific, Inc.) and microfuged at 4°C for 1 min 
at 9,000 rpm in a Beckman microfuge 12. Tubes were sectioned and the radioactivity of 
the pellet and supernatant counted. Specific binding was defined as the difference between 
total binding and the nonspecific binding occurring in the presence of a 500-fold excess 
of unlabeled IFN-7. Similar studies were carried out using membranes from bone marrow- 
derived macrophages except that membranes were incubated with IFN-7 in the following 
buffer:  25  mM  Hepes, pH  7/0.1  M  NaCl/5  mM  sodium phosphate/0.34  units per ml 
soybean trypsin inhibitor/0.5%  saponin.  Free and membrane-associated IFN were sepa- 
rated by centrifugation through 20% sucrose. 
Monoclonal Antibodies.  Monoclonal antibodies to recombinant IFN-7 were produced CELADA  ET  AL.  59 
by fusion of immune Armenian hamster splenocytes with HAT-sensitive murine myeloma 
cell lines, as will be described elsewhere.  The resulting  hybridomas were cloned three 
times  by  limiting  dilution.  Monoclonal  antibodies  were  purified  from  tissue  culture 
supernatants on a column of staphylococcal protein A Sepharose (Pharmacia  Fine Chem- 
icals, Piscataway, N  J). 
Results 
Demonstration of MAF Absorption.  For these studies,  MAF has been defined 
as  the  lymphokine  that  primes  macrophages  for expression  of nonspecific tu- 
morilytic activity toward P815 mastocytoma cells. As a source of MAF, we used 
the supernatant from a Con A-stimulated culture of the murine T cell hybridoma 
24/G1. This supernatant contained 55,000 U of MAF activity/ml and 833 IRU 
IFN-~,/ml. We have previously shown that all the MAF activity in this supernatant 
was attributable to IFN-% By titration against purified recombinant murine IFN- 
% the supernatant was estimated to contain  190 ng IFN-~/ml. 
Fig.  1 demonstrates that  MAF activity was removed from the  24/G1  super- 
natant following exposure to elicited peritoneal exudate macrophages (EPM). In 
this  experiment  1  ml  of supernatant  was diluted  1/100  (550  U/ml)  and  was 
incubated for 4 h at 37°C either in empty wells or in wells containing  6  x  106 
adherent  EPM.  The supernatant  from the control well displayed 460  U  MAF/ 
ml as compared with 530 U/ml of unincubated supernatant, indicating that MAF 
activity was stable to the 37 °C incubation. However, after exposure to EPM, the 
supernatant  contained only 92  U/ml of MAF activity. This represents an  80% 
loss of MAF activity. 
Assessment of Dose, Time, and Temperature Dependency of Absorption.  Removal 
of MAF activity from  24/G1  supernatants  was dependent on both the number 
of cells  and  the  amount  of  MAF  used  in  the  experiment.  Elicited  or  bone 
marrow-derived macrophages were equivalent in their ability to bind MAF (Fig. 
2).  Following 4  h  incubation,  50%  of the  MAF activity was removed by 1.5  x 
40"  : 
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FIGURE  l.  Demonstration of MAF absorption by macrophages, 6 x  106 EPM were incubated 
for  4  h  at  37°C  with  1  ml of 24/G1  supernatant  diluted  1/100.  As control,  the  diluted 
supernatant was incubated without macrophages. Following incubation, the supernatants were 
removed and the remaining MAF activity measured using freshly explanted macrophages. 60  RECEPTOR  FOR  INTERFERON-~,  ON  MACROPHAGES 
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FIGURE 2.  Dose-dependent absorption of MAF activity by macrophages. Different numbers 
of EPM  v~ere incubated for 4  b  at  37°C with  I  ml  of 1/100  diluted 24/G1  supernatant. 
Controls and quantitation of MAF activity were as in Fig. 1. 
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FIGURE 3.  Temperature dependence of MAF absorption. Absorption and quantitation were 
as in Fig. 1. 
106 EPM or 3 x  106 bone marrow-derived macrophages and 12 ×  106 of either 
cell population removed  100%  of the 24/G1  derived MAF. The reduction of 
MAF activity was also dependent on the initial input of the lymphokine. At MAF 
dilutions  of  1/25,  1/50,  1/100,  1/150,  and  1/200,  the  amount  of activity 
removed following treatment with 6 ×  10 6 EPM for 4 h at 37°C was 40%, 57%, 
73%, 92%, and 100%, respectively. 
Absorption was time dependent at 37°C but not at 4°C or 22°C (Fig. 3). At 
all three temperatures, exposure of 24/G1  supernatants to 6 ×  10  6 EPM for 30 
min, led to removal of ~40% of the MAF activity. Assuming that the supernatants 
contained  190  ng  IFN-3,/ml,  an  estimate  can  be  made  that  EPM  bound  or 
consumed ~2,000  molecules of IFN-T/cell. While longer incubation at 4°C or 
22°C did not result in additional removal of MAF activity, incubation at 37°C 
effected a time-dependent increase in MAF absorption. After 4 h at 37 °C, 85% 
of the MAF activity was lost from 24/G1  supernatants and all the activity was 
removed when the absorption was carried out for 24 h. Bone marrow-derived CELADA  ET  AL.  61 
macrophages were equivalent to EPM in these experiments. Similar results were 
also obtained using other 24/G1  supernatants or supernatants of Con A-stimu- 
lated normal splenic cells. 
Controls to Indicate that Removal of  MAF Activity was a Result of  Absorption.  The 
ability of macrophages to  rapidly (30  rain) remove MAF activity from 24/G1 
supernatants at 4°C suggested that the loss of activity was the result of IFN-3, 
absorption. To further substantiate this hypothesis three additional experiments 
were performed. 
To rule out the possibilities that (a) the MAF/IFN-? was degraded or altered 
by macrophage-derived factors or (b) treated macrophages produced substances 
such as prostaglandins that could interfere with the subsequent quantitation of 
MAF  activity,  a  mixing  experiment  was  performed  as  outlined  in  Table  I. 
Supernatants containing untreated MAF or MAF preincubated either in empty 
wells or with EPM were mixed in various combinations with medium from EPM- 
containing wells.  In all cases, the amount of MAF activity that was measured in 
the  mixtures closely approximated  the  theoretical  values calculated from the 
mixture composition.  No difference in  these results  were seen  when  10 -s  M 
indomethacin was present during preparation of the various supernatants. Mac- 
rophages incubated with  MAF for 2  and  4  h  absorbed  46%  and  75%  of the 
activity, respectively, in the absence of indomethacin and 42% and 74%  of the 
activity was removed in the presence of the cyciooxygenase inhibitor. 
In  a  second  series  of experiments,  paraformaldehyde-fixed or  heat-killed 
(56°C,  30  rain) EPM were compared to normal EPM for the ability to absorb 
MAF activity (Table I1). After 2 h of incubation the untreated cells had removed 
61%  of the  MAF  activity,  while  the  fixed  cells  had  removed only  38%.  At 
subsequent time points the native cells continued to absorb MAF activity, while 
the fixed  cells did  not.  Cells  heated  to  56°C  for  30  min  were  nonviable  as 
TABLE  I 
Effect of Mixing Macrophage Supernatants on Quantitation of MAF 
Activity 
Sample  Measured  Theoretical 
U/ml 
Untreated MAF (i/100)  650  -- 
Absorbed MAF*  96 
MAF incubated 4  h  (control)*  480 
M¢~ incubated with medium  ~  0  -- 
50% untreated +  50% absorbed  385  373 
50% untreated +  50%  MAF control  550  565 
50% untreated +  50%  incubated medium  300  325 
50% incubated medium +  50%  MAF control  225  240 
50% absorbed MAF +  50% MAF control  300  288 
Macrophage supernatants were  mixed and incubated  for 4  h  at  37°C 
and the MAF activity quantitated. 
* 6  x  106  EPM  were  incubated  with  1  ml  of  1/100  diluted  24/G1 
supernatant 4  h  at 37°C. 
* I  ml of diluted supernatant was incubated in an empty well  for 4  h  at 
37°C. 
! 6  x  10  ~ EPM were incubated with  1 ml of medium for 4  h at 37°C. 62  RECEPTOR  FOR  INTERFERON-~,  ON  MACROPHAGES 
TABLE [I 
Influence of Fixation or Heat Killing on Absorption of MAF Activity by Macrophage 
Percent absorption 
Treatment  Time (h)  Cytotoxic activity 
2  4  24 
%  U/ml 
None  61  80  100  46,000 
1% Paraformaldehyde  38  42  39  <100 
Heated(56°C, 30 min)  5  0  6  <100 
6 x  10  6 adherent EPM were treated with 1% paraformaldehyde  at 4°C for 1 h or heated 30 rain at 
56°C. Cells were washed and incubated at 37°C with 1 ml of 24/G1  supernatant diluted  1/100. 
r,= 
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FIGURE 4.  Absorption of MAF activity but not IL-2 activity by macrophages. 6 x  10  ~ EPM 
were incubated with i ml ofa supernatant  containing 25 U IL-2 activity/ml and 550 U MAF 
activity/ml. Incubations were performed at 37°C for 2, 4, and 24 h. 
evidenced by release of the cytoplasmic marker lactate dehydrogenase and their 
permeability  to  trypan  blue.  These  cells  did  not  express  tumoricidal  activity 
when  treated  with  24/GI  supernatants  and  also absorbed  <10%  of the  MAF 
activity even when the incubation period was prolonged to 24 h. 
A  third  set  of  experiments  was  performed  to  assess  the  specificity  of  the 
absorption.  Macrophages were  incubated  with a  supernatant  containing  25  U/ 
ml IL-2 and  550  U/ml  MAF for 2,  4, and  24  h  at  37°C.  After incubation,  the 
remaining  MAF and  IL-2 activities were quantitated  (Fig.  4).  When  compared 
to the corresponding control,  IL-2 showed  17%,  4%, and  13% absorption after 
2, 4, and 24 h, respectively, while for the same periods of incubation, 45%, 83%, 
and  100% of MAF was absorbed. Similar results were obtained using 50 or  12.5 
U/ml  of  IL-2.  The  variation  between  the  values  obtained  for  the  IL-2  after 
incubation  with  macrophages  was  similar  to  the  variation  obtained  with  the 
control values, suggesting that IL-2 was not absorbed by macrophages. 
Relationship  between  Time  of Absorption  and  Development  of Cytotoxicity.  To 
study the  relationship between  absorption and development of the  tumoricidal 
response, macrophages were incubated at 37 °C with the 24/G1  supernatant for CELADA  ET  AL.  63 
periods of time between 1 and 6 h. After each incubation period, the supernatant 
was removed and analyzed for MAF activity while the macrophages were washed 
and then challenged with P815 in the presence of a second signal (HKLM). Fig. 
5  shows that although MAF is absorbed progressively over the period of incu- 
bation,  a  minimum exposure of 4  h  is  required before the macrophage can 
express tumorilytic activity. During this critical period of incubation, 82% of the 
MAF has been absorbed.  No change was observed in the minimum incubation 
time needed to elicit a tumoricidal response when higher concentrations of MAF 
were used. 
Cell and Species Specificity of Absorption.  Elicited and resident peritoneal exu- 
date murine macrophages are known to differ in their responsiveness to IFN-% 
In our experimental assay system, only the freshly explanted elicited cell popu- 
lation developed IFN-dependent nonspecific tumorilytic activity (Table III). This 
responsiveness was rapidly lost in culture and was also not expressed by freshly 
explanted or cultured resident peritoneal exudate cells. Table III shows that the 
defect is not related to IFN-'y binding by the cells, since both the responsive and 
100. 
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FIGURE 5.  Correlation of MAF absorption and development of cytolytic activity. 6  x  106 
EPM  were  incubated  for  the  time  indicated  with  1/100  diluted  24/G1  supernatant.  The 
resulting absorbed supernatants  were assayed for remaining MAF activity. The macrophages 
used for absorption were mixed with 6 x  105 ~ltIn-labeled P815 tumor cells, 6 X l0  T HKLM 
(as a second signal) and 10 -6 M indomethacin in a total volume of 1 ml. After 18 h in culture, 
0.5  ml  of supernatant  was  removed,  the  radioactivity counted  and  the  cytolytic activity 
calculated (O""O). 
TABLE  III 
Cytotoxic Activity and MAF Absorption by Elicited and Resident 
Peritoneal Macrophages 
Percent 
Macrophages  Cytotoxic 
(6 X 10  6)  Condition  activity  absorptiOn*after  4 h 
(MAF U/ml)  incubation 
Elicited  Freshly explanted  48,000  78 
3-d culture  <200  61 
Resident  Freshly explanted  <200  60 
3-d culture  <200  65 
* 1 ml of 24/G1 supernatant diluted  1/100 was used for each absorption 
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unresponsive  cells absorbed  comparable  amounts of MAF activity when  incu- 
bated for 4  h  at 37°C  (78%  and 60-65%,  respectively). In other experiments 
(data  not  shown)  macrophages  from  eight  different  inbred  and  two  outbred 
strains of mice were tested for their ability to express IFN-3,-dependent tumori- 
cidal  activity and  to  absorb  MAF  activity from  the  24/G1  supernatant.  The 
inbred mouse strains tested included C3HeB/FeJ (H2k),  C3H/HeJ (H2k),  CBA/ 
CaJ (H2k),  a/J  (H2a),  C57BL/6J (H2b),  DBA/2J (H2a),  SJL (H2S), and C3D~ F,/J 
(H2 k X  H2Cl). Although  the  various  macrophages  expressed  different levels  of 
tumorilytic activity, they all absorbed nearly identical amounts of MAF activity 
during  incubation  periods  of 2,  4,  or  24  h.  Thus  absorption  was  not  H-2 
restricted. 
Table IV compares a variety of murine cell lines for their ability to absorb 24/ 
Gl-derived  MAF  activity.  Murine  fibroblasts  (L929), fibrosarcomas  (TU5  and 
1023),  mastocytomas (P815),  and T  cell hybridomas (TH4.4,  24/G1  and  1.19) 
all absorbed MAF activity at 37 °C in a time-dependent fashion. Two macrophage 
cell lines (P388D~  and J774)  were identified that were deficient in their ability 
to bind natural IFN-3,. Even after 24 h  incubation, P388D~  absorbed only 37% 
of the  MAF activity and J774  only 60%,  while all other cell lines and normal 
peritoneal  exudate  macrophages  had  absorbed  93-100%  of the  activity.  In 
addition to their reduced ability to bind IFN-3', P388D~ and J774 also displayed 
a  quantitative  defect  in  their  ability to  mount an  IFN-dependent  nonspecific 
tumorilytic  response.  When  24/G1  supernatants  were  titrated  on  control 
C3HeB/FeJ macrophages,  a  value of 43,800  U  of MAF activity was obtained. 
However, values of only 320 U  and 4,300  U  were obtained when the assay was 
performed with P388Dl  or J774,  respectively. When examined after 6  h  incu- 
bation with the hybridoma supernatant, the two cell lines also showed a defective 
TABLE  IV 
Absorption  of MAF Activity by Murine Cell Lines 
Cell type 
Time of incubation (h) 
2  4  24 
EPM control  47  88  100 
L929"  22  33  93 
TU5*  33  60  100 
1023'  35  72  100 
P8150  61  93  100 
TH4.4  u  37  68  95 
24/G1 j  33  97  100 
1.191  52  97  100 
P388DI ~  0  10  37 
J774  ~  12  25  60 
In all the cases 6 x  106 cells were incubated 
ml of 24/G1 supernatant diluted 1/100. 
* Fibroblast. 
* Fibrosarcoma. 
a Mastocytoma. 
I T cell hybridoma. 
Macrophage cell line. 
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spreading reaction. Although 82% of the control cells had spread, only 15% of 
P388DI and 22% ofJ774 had undergone morphological changes. 
Table V compares cells from a number of different species for their ability to 
absorb 24/Gl-derived  MAF activity. Absorption appears to display a degree of 
species  specificity.  When  peritoneal  exudate  macrophages  from  four  rodent 
species were compared, only murine cells absorbed MAF activity during the first 
4 h of incubation. After 24 h of incubation, rat macrophages were also found to 
absorb or consume a small amount (37%) of MAF activity. Human polymorpho- 
nuclear leukocytes, lymphocytes, and erythrocytes did not absorb murine MAF. 
However,  human  monocytes absorbed  33%  of the  activity  following in  vitro 
culture  for  24  h.  This result  agrees  with  the observation  that after  1-3  d  in 
culture,  human peripheral  blood  monocytes acquire  the ability  to respond to 
murine IFN-3, and can express nonspecific tumoricidal activity toward the human 
melanoma cell line A357 (Buchmeier, N. A., and R. D. Schreiber, unpublished 
observation).  In  contrast  to normal  human peripheral  blood cells, the  human 
histiocytic  lymphoma  cell  line  Ugs7 was  quantitatively  equivalent  to  murine 
macrophages in effecting absorption of 24/Gl-derived MAF activity. 
Absorption of Recombinant IFN-y by Macrophages.  We have previously found 
that  the MAF  activity  displayed  by  purified  recombinant  murine  IFN-3,  was 
equivalent, on an antiviral activity basis, to the MAF activity expressed by the T 
cell hybridoma-derived IFN-3, (27). This observation prompted a comparison of 
the ability of macrophages to absorb natural arid recombinant IFN-3,. For these 
experiments,  the  recombinant  1FN-3,  was  diluted  such  that  the  final  solution 
contained the same amount of MAF activity as a  1/100  dilution of the 24/G1 
supernatant  (550  U/ml).  After  2  and  4  h  incubation  with  normal  EPM  the 
amount of absorption of the recombinant IFN-3,  (32%  and  76%,  respectively) 
was similar to that of the natural  IFN (44%  and 86%,  respectively, Table  VI). 
Moreover,  P388D~  that was deficient in absorbing the natural  IFN-3, was also 
deficient in absorbing the recombinant material. 
In order to directly visualize the interaction of IFN-3,  with the macrophage 
TABLE  V 
Species Specificity of MAF Absorption 
Time of incubation (h) 
2  4  24 
Macrophages 
Mouse  47  88  100 
Rat  0  0  37 
Hamster  0  0  0 
Guinea Pig  ND  0  0 
Human cells 
Monocytes  0  0  33 
Polymorphonuclear leukocytes  0  0  0 
Lymphocytes  0  0  8 
Erythrocytes  0  0  0 
Ugs7  47  94  1 O0 
Absorption conditions as in Table IV. 
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TABLE VI 
Absorption of Recombinant 1FN-~, by EPM and P388DI 
Percent absorption 
Recombinant 
IFN-~,  24/Gl-IFN-3, 
2b  4h  2h  4h 
% 
Control macrophages  32  76  44  86 
P388Dj  0  3  0  8 
6 x  10  ~  cells were incubated for 2 or 4 h in the presence of 1 ml of 24/ 
G1 supernatant  or recombinant  1FN-7 diluted  such that both preparations 
displayed 550 U of MAF activity  per ml. 
surface, recombinant IFN-3,  was bound to fluorescent microspheres and incu- 
bated  at  4°C  with  macrophage  populations.  EPM  exposed  to  microspheres 
bearing IFN-7 bound one to nine beads per cell  (Fig. 6a).  Staining of the cell 
population  was  heterogeneous with  35%  of the  cells  binding less  than  three 
beads.  When microspheres were  used that did not carry IFN-% but that had 
been blocked by incubation with ethanolamine, no binding occurred (Fig. 6b). 
Preincubation of EPM with high concentrations of 24/G 1 supernatant, abrogated 
binding of IFN-7-covaspheres, indicating that binding was IFN mediated (Fig. 
6c).  Fig. 6d shows that P388D~  did not bind IFN-7-coated microspheres. This 
result thus agrees with the absorption data. 
Demonstration  of a Specific  IFN-7  Receptor  on Macrophages:  Quantitation  of the 
Interaction  between  Recombinant  IFN-7  and  Macrophages.  The  data  presented 
thus far indicate that natural and recombinant IFN-3, bound to macrophages in 
a  similar fashion. Because of its availability, the purified recombinant material 
was used to quantitate the interaction of IFN-~,  with the macrophage surface. 
Recombinant IFN-7  was  first subjected to HPLC gel filtration to remove any 
degraded material that may have formed during storage. As detected by ultra- 
violet absorption  at  280  nM,  two  molecular  weight  species  eluted  from  the 
column  with  symmetrical  elution  profiles  (data  not  shown).  The  first  peak 
displayed  an  apparent  molecular  weight  of  32,000,  while  the  second  peak 
corresponded to an Mr of 5,000-7,000.  Only the material in the 32,000-dalton 
peak expressed MAF and antiviral activities and reacted with monoclonal anti- 
bodies to IFN-% 
Fig.  7  shows  the results of a  binding experiment that used bone  marrow- 
derived macrophages and 125I-labeled HPLC-purified recombinant IFN-7. Spe- 
cific binding has been defined as the binding that is inhibited in the presence of 
a  500-fold excess of unlabeled IFN-7.  In these experiments -80% of the total 
binding was specific. By Scatchard plot analysis, the cells  were found to carry, 
per cell, 15,200 receptors that bound ligand in a homogeneous, noncooperative 
manner and displayed an affinity (Ka) of 1.18  X 10  s M  ~1. The average of three 
such experiments produced mean values of 12,000  receptors per cell and a Ka 
of 0.9  x  l0 s M  -1.  Analysis of IFN-3,  binding to P388Da  indicated that the cell 
line carried only 760  receptors per cell, which is 6.3%  that displayed by bone 
marrow-derived macrophages. Similar experiments were performed on mem- C
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FIGURE 7.  Quantitation of IFN-3, binding to murine macrophages. 5  X  l0  e bone marrow- 
derived macrophages were incubated at 4°C for 2  h  with different amounts of radiolabeled 
HPLC  purified,  recombinant IFN-~'.  Cell  associated  and  free  ~I-IFN  were  separated  by 
centrifugation over pthalate oil as outlined in Materials and Methods. Specific binding was 
defined as the difference between total binding and the nonspecific binding occurring in the 
presence of a 500-fold excess of unlabeled IFN-3'. The insert represents Scatchard plot analysis 
of the data. B, bound IFN-3, and F, free IFN-3,. 
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FIGURE 8.  Specificity experiments for recombinant ~2sI-IFN-7  binding to macrophage. Bone 
marrow-derived macrophages were preincubated for 30 min at 4°C with designated amounts 
of competitor in a total reaction volume of 100 pl. 20 #1 of l~Sl-recombinant IFN-~ (290 IRU) 
was then added to each tube and incubation continued for 2 h at 4°C. Specific binding and 
separation of bound and free ~251-1FN-3, as in Fig. 7.  For these studies the T  cell hybridoma 
supernatant or a sham supernatant were concentrated 10-fold before use by ultrafihration. 
brane preparations of bone marrow-derived macrophages. These studies showed 
that  17 #g of membranes (weight recovered from  107 cells) specifically bound a 
maximum of 5 ng of IFN-3'. 
Fig.  8  demonstrates the specificity of the binding reaction.  Preincubation  of 
the bone marrow macrophages with different amounts of 24/Gl-derived IFN-y 
inhibited  the  uptake  of 125I-recombinant  IFN-3'  in  a  dose-dependent  fashion. 
Addition  of 208  IRU  of natural  IFN-y to the  reaction  mixture  caused a  62% 
reduction in binding of a comparable amount of the recombinant material (290 CELADA  ET  AL.  69 
IRU),  indicating  that  the  two  products  bound  to  the  cells  with  comparable 
affinity. Crude preparations of IFN-/3 displayed a weak ability to inhibit binding 
of recombinant IFN-3,  when added in  large excess (8,000  IRU),  while IFN-a 
displayed no inhibitory activity at all. 
Relationship between Receptor Binding and Macrophage Activation.  Two mono- 
cional antibodies to  IFN-~,  (H2 and  H21)  that differentially modulate IFN-3,- 
dependent biological responses in  macrophages were used to demonstrate the 
involvement of the  IFN-'y receptor in  macrophage activation.  H21  has  been 
found to inhibit the ability of IFN-3' to induce nonspecific tumorilytic activity or 
Ia expression in macrophages, while H2 was found to enhance these activities. 2 
Fig. 9 shows that inhibition or enhancement of IFN-induced macrophage func- 
tions correlates with the interaction of IFN-~ with the IFN-'), receptor. Depending 
on the input of IFN-"y, an excess of H21  inhibited  100% of the cellular uptake 
of IFN-3,,  while  H2  enhanced binding as  much as  3.3-fold.  No alteration  of 
binding was observed when normal hamster IgG was substituted for the mono- 
clonals. 
Discussion 
This report documents the existence of a  IFN-~r-receptor on murine macro- 
phages and indicates that receptor engagement is a  necessary first step in  the 
induction of nonspecific tumorilytic activity in these cells. Macrophages bound 
either purified recombinant IFN-~ produced in bacteria or natural IFN-'y derived 
from either a murine T  cell hybridoma or normal murine splenic cells. Binding 
was  specific,  saturable,  of high  affinity,  and  resulted  in  the  induction  of a 
biological response in appropriate  macrophage populations.  These parameters 
thus indicate that IFN-~ was binding to a specific cell surface receptor. 
Although substantial  quantities  of purified natural  murine IFN-'y were not 
available for these studies, the interaction could be demonstrated by quantitating 
the macrophage-dependent absorption of I FN-~ from supernatants of stimulated 
T  lymphocytes. We chose to quantitate MAF activity as an indicator of IFN-'y, 
6- 
~3- 
z 
H2 
•  =  T 
50  100  150 
tFN Offered (rig) 
FIGURE 9.  Effect of monoclonal antibodies on IFN-3, uptake by macrophages. 5 X 106 bone 
marrow-derived macrophages were incubated for 2 h at 4°C with the indicated amounts of 
12sI-IFN-3, in the presence of medium (0), normal hamster IgG (O), monoclonal anti-IFN, H2 
(A) or monoclonal anti-IFN, H21  (&). Specific binding and separation of cell-associated '2sI- 
IFN-3, as in Fig. 7. 70  RECEPTOR FOR  INTERFERON-q, ON  MACROPHAGES 
since the macrophage was the target cell for this activity and since the MAF assay 
was  more quantitative and  10  times more sensitive than  the antiviral activity 
assay. For most of the studies, a supernatant of the 24/G1  T  cell hybridoma was 
used.  Previous studies have shown  that  the MAF activity produced by 24/G1 
was largely due to  IFN-3,  (6,  8,  27).  Recently, using monoclonal antibodies to 
recombinant  IFN-'y we have  found that  IFN-"r represented the only MAF  in 
these  supernatants  and  in  Con  A-stimulated supernatants  of normal  murine 
splenic cells,  z The absorption experiments showed that the ability of macrophages 
to  remove  MAF  activity  from  culture  supernatants  was  dependent  on  cell 
number, temperature, time of incubation, and displayed species specificity. The 
data also indicated that the activity was removed by cellular absorption and not 
by extracellular degradation or production of macrophage-derived factors that 
interfered with MAF quantitation. This conclusion was supported by the obser- 
vations that (a) absorption occurred at 4 o  C, (b) paraformaldehyde-fixed murine 
macrophages absorbed MAF activity, (c) absorption of 24/G1  MAF was effected 
by murine macrophages but not hamster- or guinea pig-derived cells, (d) absorp- 
tion was specific since treated supernatants showed a selective reduction in MAF 
activity but not I L-2 activity, and (e) mixing 24/G 1 supernatants with macrophage 
culture supernatants did not affect the levels of MAF activity. 
While these results strongly suggested the existence of an IFN-3,  receptor on 
murine macrophages, they had to be validated with quantitative uptake experi- 
ments using radiolabeled IFN-y. This was accomplished with ~2~I-labeled purified 
recombinant IFN-3'. Scatchard plot analysis of the binding data showed that the 
binding of IFN-7 to macrophages at 4°C was noncooperative (linear Scatchard 
plots),  saturable  (~12,000  receptors/cell), specific (binding was  inhibitable  by 
unlabeled IFN-3'), and of moderately high affinity (K  a =  0.9  X  10 8 M-I), Binding 
could be demonstrated to membrane preparations as well as to intact cells. 
Several lines of evidence indicated that the interaction of the receptor with 
natural IFN-3,  was comparable to that observed with the recombinant material. 
Both  types of IFN-y  expressed  equal  MAF  activities  when  compared on  an 
antiviral activity basis (8, 27). Hybridoma-derived and recombinant IFN-3' were 
absorbed in an identical fashion by normal macrophages and were not absorbed 
by  the  P388D1  cell  line.  Subsequent  quantitation  of ~25I-recombinant IFN-3, 
binding  to  this  cell  line  indicated  that  P388D1  carried  only  6.3%  as  many 
receptors as were expressed on normal macrophages. The number of receptors 
on normal macrophages determined by the absorption experiments with natural 
IFN-3, (2,000-5,000  receptors/cell) was comparable to the number obtained by 
measurement of l~5I-recombinant IFN-y binding (12,000 receptors/cell). Finally, 
unlabeled, natural IFN-3,  could quantitatively compete with the labeled recom- 
binant material for receptor binding. This result indicated that the two IFN-3' 
preparations bound to the receptor with similar affinities. 
The  monoclonal antibody studies indicate that  binding  of IFN-y to  its  cell 
surface receptor is a necessary step for the induction of a biological response in 
macrophages. Modulation of the binding reaction correlated with appropriate 
increases or decreases in the eventual induction of tumoricidal activity. It is most 
likely that  the inhibition  produced by  H21  reflected its ability  to  directly or CELADA  ET  AL.  71 
sterically block regions of IFN-~,  that interact with the receptor. The enhance- 
ment  observed  with  H2  probably  reflects the  formation  of soluble  immune 
complexes that were multimeric with respect to IFN-~,  and that formed multi- 
point attachments to the macrophages through IFN-~, receptors. These possibil- 
ities are currently under examination. 
The results presented in this communication are consistent with observations 
made in other laboratories. The ability of macrophages to remove MAF activity 
from lymphokine preparations was previously reported by Yamamoto and To- 
kunaga (28).  However, this earlier study used a  MAF of unknown biochemical 
identity and failed to establish absorption as the mechanism for MAF removal. 
A  number of other studies have  indicated that  MAF-dependent induction of 
tumoricidal  activity  is  not  H2  restricted  (29).  Our  experiments support  this 
conclusion, since macrophages from mice with  different H2  backgrounds ab- 
sorbed MAF activity to comparable degrees. 
The  species  specificity of the  binding  agrees  with  other  results  obtained 
independently. Although murine IFN-y did not bind to hamster or guinea pig 
macrophages, it did bind to cultured normal human monocytes and to the human 
histiocytic lymphoma cell line U937. Both natural and recombinant murine IFN- 
y have been found to activate normal human peripheral blood monocyte-derived 
macrophages for nonspecific tumoricidal activity (Buchmeier, N. A., and R. D. 
Schreiber, unpublished data).  Moreover, unlabeled recombinant murine IFN-3, 
can  inhibit  binding  of ~25I-human recombinant IFN~" to  human  mononuclear 
phagocytes (Celada, A., and R. D. Schreiber, manuscript in preparation). These 
results  thus clearly differentiate IFN-~,-dependent MAF  activity from  IFN-y- 
antiviral activity on fibroblasts. The latter displays strict species specificity. 
To date only one other series of studies exists that suggests the existence of a 
cellular IFN-y receptor. Anderson et al (30, 31) have demonstrated binding of 
purified natural human IFN-y to human GM-258 fibroblasts. These fibroblasts 
expressed 8,000-20,000  receptors/cell and  bound ligand with a Kd of 2-6  × 
10 -9 M (or a K~ of 1.7-5  X l0 s M-l). These parameters are similar to the values 
obtained  in  our  study.  We  have  also  documented the  presence of an  IFN-'y 
receptor on the murine fibroblast cell line L9~9 as well as several other cell types 
using the MAF absorption technique. However, it is not yet known whether the 
receptors on the different cell types are identical or distinct. More structural and 
immunochemical data about the IFN-'r receptor is needed before this question 
can be answered. Work  is currently underway to isolate and characterize the 
macrophage ]FN-'y receptor. 
The identification of a IFN-y receptor on macrophages that participates in the 
induction of nonspecific tumoricidal activity is  the first step at  understanding 
macrophage activation at the molecular level. Work is currently in progress to 
determine the fate of the receptor-bound ligand and whether receptor engage- 
ment is  sufficient to  initiate  a  tumoricidal response.  The quantitation  of this 
receptor-ligand interaction should also provide a  means of defining the mecha- 
nisms of action of other factors that have been reported to have MAF activity 
but not antiviral activity (32-34). 72  RECEPTOR FOR  INTERFERON-~' ON  MACROPHAGES 
Summary 
Gamma-interferon  (IFN-~)  is  the  macrophage-activating  factor  (MAF)  pro- 
duced by normal murine splenic cells and the murine T  cell hybridoma 24/G 1 
that induces nonspecific tumoricidal activity in macrophages.  Incubation of 24/ 
G1  supernatants  diluted to 8.3  IRU IFN--y/ml with 6  x  106 elicited peritoneal 
macrophages or bone marrow-derived  macrophages for 4  h  at 37°C,  resulted 
in removal of 80% of the MAF activity from the lymphokine preparation.  Loss 
of activity appeared to result from absorption and not consumption because (a) 
40% of the activity was removed after exposure to macrophage  for 30 min  at 
4 ° C, (b) no reduction of MAF activity was detected when the 24/G 1 supernatant 
was incubated with macrophage culture supernatants, and (c) macrophage-treated 
supernatants showed a selective loss of MAF activity but not interleukin  2 (IL,2) 
activity. Absorption was dependent on the input of either IFN-~, or macrophages 
and was time dependent at 37 °C but not at 4 o  C. With four rodent species tested, 
absorption  of murine  IFN-3,  displayed  species  specificity.  However,  cultured 
human  peripheral  blood monocytes and  the  human  histiocytic  lymphoma  cell 
line U937 were able to absorb the murine lymphokine. Although the majority of 
murine cell lines tested absorbed 24/G1  MAF activity, two murine macrophage 
cell lines, P388D~ and J774, were identified which absorbed significantly reduced 
amounts of natural  IFN-7. Purified murine recombinant IFN-3, was absorbed by 
elicited macrophages but not by P388D~. Normal macrophages but not P388D~ 
bound fluoresceinated microspheres coated with recombinant IFN-y and binding 
was  inhibited  by pretreatment  of the  normal  cells  with  24/G1  supernatants. 
Scatchard plot analysis showed that 12,000 molecules of soluble 125I-recombinant 
IFN-7 bound per bone marrow macrophage with a Ka of 0.9 x  10  s M -l. Binding 
was quantitatively inhibitable by natural  IFN-3  ~ but not by murine IFN~. IFN-/3 
competed only weakly. Monoclonal antibodies against IFN-2¢ either inhibited or 
enhanced MAF activity by blocking or increasing IFN-7 binding to macrophages, 
respectively. These results indicate that IFN-7 reacts with a receptor on macro- 
phage in a specific and saturable manner and this interaction initiates macrophage 
activation. 
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